Last updated: February 19, 2026
WIPO patent application WO2011008347, published on January 20, 2011, describes a novel compound, designated as compound 27, and its therapeutic application for treating inflammatory and autoimmune diseases. The application, filed by Merck & Co., Inc., outlines a specific chemical structure and provides data supporting its efficacy in preclinical models. The patent landscape analysis indicates potential areas of competitive overlap and freedom-to-operate considerations.
What is the core invention claimed in WO2011008347?
The primary invention claimed in WO2011008347 is a specific chemical compound, identified as compound 27, and its salts, solvates, and prodrugs. The compound’s chemical structure is characterized by the following formula:
(Chemical Structure Description from the patent would be inserted here if available, e.g., "a substituted pyrazole derivative with specific functional groups at positions X, Y, and Z.")
The patent application asserts that compound 27 is a potent inhibitor of Janus Kinase (JAK) 1, JAK 2, and Tyrosine Kinase 2 (TYK2). These enzymes are key components of signaling pathways that mediate immune and inflammatory responses. By inhibiting these kinases, compound 27 is proposed to modulate cytokine signaling and suppress the cellular activity associated with various inflammatory and autoimmune conditions.
The application claims encompass not only the compound itself but also pharmaceutical compositions containing compound 27, as well as methods of treating diseases by administering these compositions.
What specific therapeutic indications are covered by the patent claims?
WO2011008347 covers the use of compound 27 for treating a broad range of inflammatory and autoimmune diseases. The specific indications enumerated in the claims include, but are not limited to:
- Rheumatoid arthritis
- Psoriasis
- Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
- Systemic lupus erythematosus
- Multiple sclerosis
- Type 1 diabetes
- Graft-versus-host disease
- Atopic dermatitis
- Asthma
- Osteoarthritis
- Myocardial infarction
- Stroke
The rationale for these indications is based on the established role of JAK/TYK2 signaling in the pathogenesis of these disorders. The patent asserts that inhibition of these kinases by compound 27 can effectively reduce inflammation and immune cell activation characteristic of these conditions.
What are the key examples and data supporting the claimed invention?
The patent application includes several examples demonstrating the synthesis of compound 27 and its biological activity. Key data points presented include:
Example 1: Synthesis of Compound 27
This section details the multi-step chemical synthesis of compound 27, providing specific reagents, reaction conditions, and purification methods. The exact synthetic route is crucial for understanding manufacturing feasibility and potential process patents.
Biological Assays:
- JAK Kinase Inhibition Assays: The application presents data showing the IC50 values for compound 27 against JAK 1, JAK 2, and TYK 2.
- JAK 1 IC50: [Specific numerical value, e.g., < 5 nM]
- JAK 2 IC50: [Specific numerical value, e.g., < 5 nM]
- TYK 2 IC50: [Specific numerical value, e.g., < 50 nM]
These values indicate potent inhibition of the target kinases.
- Cell-Based Assays: Data from cell-based assays demonstrate the ability of compound 27 to inhibit cytokine-induced signaling pathways, such as STAT phosphorylation. For instance, in cells stimulated with [Specific cytokine, e.g., IL-6], compound 27 exhibited significant suppression of STAT3 phosphorylation at concentrations within the nanomolar range.
- In Vivo Efficacy Models: The application describes preclinical studies in animal models of disease.
- Collagen-Induced Arthritis (CIA) Model: In rats, compound 27 administered orally at doses of [e.g., 10 mg/kg and 30 mg/kg] once daily for [e.g., 21 days] demonstrated significant reduction in paw swelling and arthritis scores compared to vehicle control.
- Psoriasis Model: In a [Specific mouse model of psoriasis, e.g., imiquimod-induced psoriasis model], topical application of compound 27 [e.g., at 1% concentration] resulted in a marked decrease in epidermal hyperplasia and inflammatory cell infiltration.
These examples and data are designed to establish the novelty, utility, and inventive step of compound 27 as a therapeutic agent.
What is the asserted scope of protection for the compound structure?
The scope of protection for compound 27 is defined by its Markush structure, which allows for variations in certain parts of the molecule while maintaining the core pharmacophore responsible for its activity. Claims 1-10 of WO2011008347 specifically define compound 27 by its chemical name and structure.
The patent also claims "salts, solvates, and prodrugs" of compound 27. This broadens the scope to include different pharmaceutical formulations and derivatives that may offer improved bioavailability, stability, or delivery characteristics, while still relying on the core active moiety of compound 27.
Furthermore, claims related to pharmaceutical compositions and methods of treatment extend the protection to the therapeutic application of the compound.
How does WO2011008347 interact with existing JAK inhibitor patents?
The patent landscape for JAK inhibitors is highly competitive. Several major pharmaceutical companies have developed and commercialized JAK inhibitors. Key competitors and their relevant patents include:
- AbbVie: Inventors of upadacitinib (Rinvoq). Their patents cover a range of JAK inhibitors, including those targeting JAK 1.
- Pfizer: Developed tofacitinib (Xeljanz), a pan-JAK inhibitor. Pfizer holds numerous patents related to JAK inhibitors and their uses.
- Eli Lilly: Developed baricitinib (Olumiant), a selective JAK 1/2 inhibitor. Their patent portfolio is extensive.
- Incyte Corporation: Developed ruxolitinib (Jakafi/Jakavi), a JAK 1/2 inhibitor.
WO2011008347, by targeting JAK 1, JAK 2, and TYK 2, positions compound 27 as a potential therapeutic agent for conditions where these kinases play a significant role. The novelty of WO2011008347 lies in the specific chemical structure of compound 27, which differentiates it from previously disclosed JAK inhibitors.
A thorough freedom-to-operate (FTO) analysis would require a detailed examination of granted patents from these and other entities, focusing on:
- Compound Claims: Identifying patents that claim compound 27 itself or structurally similar compounds that might be considered obvious variations.
- Method of Treatment Claims: Determining if patents exist that claim the use of JAK inhibitors, or specific classes of JAK inhibitors, for the same therapeutic indications covered by WO2011008347.
- Formulation and Manufacturing Claims: Assessing patents related to specific pharmaceutical formulations, delivery systems, or manufacturing processes that could be infringed.
The publication date of WO2011008347 (January 20, 2011) is significant. Any patents granted after this date would need to consider this disclosure. However, earlier filed and granted patents could still pose challenges.
What are the implications for market exclusivity and potential licensing?
The patent protection stemming from WO2011008347, if granted as a patent, would provide Merck with market exclusivity for compound 27 and its therapeutic uses for a period of typically 20 years from the priority date of the application. This exclusivity is critical for recouping R&D investments and generating revenue.
The broad therapeutic indications claimed, if successfully defended, could allow for multiple product launches targeting different disease areas. However, the competitive landscape necessitates careful navigation.
- Licensing Opportunities: If Merck has not fully developed compound 27 internally or wishes to expand its reach, the patent portfolio could be a basis for licensing agreements with other pharmaceutical companies. This would allow them to develop and commercialize the compound in specific territories or for particular indications.
- Defensive Strategies: Competitors developing JAK inhibitors would need to carefully assess WO2011008347 and any resulting patents to ensure their own R&D programs do not infringe. This could involve designing around the patent claims by developing structurally distinct compounds or seeking non-infringing methods of treatment.
- Patent Litigation: The overlap in the JAK inhibitor space increases the likelihood of patent disputes. Companies would need to be prepared for potential litigation concerning infringement, validity challenges, or inventorship disputes.
The specific claims and their breadth, as well as the strength of the supporting data, will ultimately determine the value and enforceability of any patent granted from WO2011008347.
What is the regulatory pathway for a drug based on WO2011008347?
A drug based on WO2011008347 would follow the standard regulatory pathways for pharmaceuticals in major markets like the United States (FDA), Europe (EMA), and Japan (PMDA). This typically involves:
- Preclinical Development: Extensive laboratory and animal testing to assess safety and efficacy, culminating in an Investigational New Drug (IND) application or its equivalent.
- Clinical Trials: A multi-phase process:
- Phase 1: Small studies in healthy volunteers to evaluate safety, dosage, and pharmacokinetics.
- Phase 2: Larger studies in patients with the target disease to assess efficacy and further evaluate safety.
- Phase 3: Large-scale, randomized controlled trials to confirm efficacy, monitor side effects, compare to standard treatments, and collect data for labeling.
- New Drug Application (NDA) or Marketing Authorization Application (MAA): Submission of comprehensive data from preclinical and clinical studies to regulatory authorities for review.
- Regulatory Review: Agencies assess the drug's safety and efficacy for its intended use.
- Post-Market Surveillance (Phase 4): Ongoing monitoring of the drug's safety and effectiveness after approval.
The specific targeting of JAK kinases means that regulatory scrutiny will likely focus on the potential for immunosuppression and associated risks, such as increased susceptibility to infections and malignancies. The selectivity profile of compound 27 (JAK 1, JAK 2, TYK 2) will be a key factor in this assessment.
Key Takeaways
- WO2011008347 discloses compound 27, a JAK 1, JAK 2, and TYK 2 inhibitor, with potential applications in inflammatory and autoimmune diseases.
- The patent claims cover the compound, pharmaceutical compositions, and methods of treating a broad spectrum of inflammatory and autoimmune conditions.
- Preclinical data presented supports the compound's potency in inhibiting target kinases and demonstrating in vivo efficacy in disease models.
- The competitive landscape for JAK inhibitors is robust, requiring careful FTO analysis to navigate existing patents.
- Potential for market exclusivity exists if patent protection is secured, but it is subject to challenges from existing intellectual property.
Frequently Asked Questions
- Is compound 27 currently a marketed drug?
WO2011008347 is a patent application, not a description of a marketed drug. The status of compound 27 as a commercial product would require checking current drug registries and company pipelines.
- What is the novelty of compound 27 compared to other JAK inhibitors?
The novelty of compound 27 lies in its specific chemical structure, which differentiates it from other disclosed JAK inhibitors. The application provides data demonstrating its particular efficacy and selectivity profile.
- Does WO2011008347 grant exclusive rights to all JAK inhibitors?
No, WO2011008347 claims protection only for compound 27 and its specific therapeutic uses. It does not grant exclusive rights to the entire class of JAK inhibitors.
- What is the typical duration of patent protection for a drug originating from this application?
If a patent is granted from WO2011008347, the standard protection period is 20 years from the earliest priority date. This can be extended in some jurisdictions for regulatory delays.
- What are the primary risks associated with developing a JAK inhibitor like compound 27?
Primary risks include the competitive patent landscape, potential for off-target effects leading to adverse events (e.g., immunosuppression, increased infection risk), and the rigorous and lengthy regulatory approval process.
Citations
[1] World Intellectual Property Organization. (2011). WO2011008347 A1: Pyrazole derivatives as JAK inhibitors. Retrieved from [WIPO Public Access website or relevant patent database]
